MedTrace Logo

A Comparative Study of the Pharmacokinetics of SIM0718 Injection in Healthy Adult Subjects in China

NCT06701149 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2026-04-03

No results posted yet for this study

Summary

A study to compare the pharmacokinetics, safety and immunogenicity of SIM0718 injection in healthy adult subjects in China

Conditions

  • Healthy Adult Subjects

Interventions

DRUG

Rademikibart injection

300 mg administered subcutaneously on the first day

DRUG

CBP-201 injection

300 mg administered subcutaneously on the first day

Sponsors & Collaborators

  • Simcere Pharmaceutical Co., Ltd

    lead OTHER

Principal Investigators

  • wen qing · Jinan Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-28
Primary Completion
2025-05-22
Completion
2025-05-22

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06701149 on ClinicalTrials.gov